What's New in Lyme Disease
JAMA has published an overview of new considerations on Lyme disease, focusing on Diagnostics, Vaccines, and Prevention.
Read ArticleSearch for Terms or Answers
JAMA has published an overview of new considerations on Lyme disease, focusing on Diagnostics, Vaccines, and Prevention.
Read ArticleEosinophilic granulomatosis with polyangiitis (EGPA) has long been managed by extrapolating results from microscopic polyangiitis and granulomatosis with polyangiitis clinical trials. But new insights into EGPA's has lead to advances in therapy and new treatment paradigms.
Read ArticleThe rheumatology, genetics and NIH communities mourn for Dr. Daniel L. Kastner, who died on July 28, 2026, in Bethesda, Maryland, at age 74. The following are declarations, tributes, and memories dedicated to this mensch of a man, titan of science, memorable mentor and humble physician.
Read ArticleA new review in the Journal of Cardiovascular Development and Disease (Tamirisa et al) synthesizes how systemic lupus erythematosus, rheumatoid arthritis, and systemic sclerosis have an increased risk of arrhythmias and sudden cardiac death attributable to shared immune pathways.
Read ArticleJuly is Juvenile Arthritis Awareness Month, and while many people think of arthritis as a disease of aging, nearly 300,000 children in the U.S. are living with a rheumatic disease.
Equally important is that 2026 marks a 50 year anniversary for Pediatric
Read Article
Dr. Jack Cush reviews the news, journal reports from the past week on RheumNow.com.
Read Article
EULAR recommends a combination of glucocorticoids with either rituximab or cyclophosphamide for remission induction in life-threatening or organ-threatening AAV, followed by gradual tapering of glucocorticoids.
Read ArticleBeck et al has published a review of the VEXAS syndrome in The Lancet, focusing on the pathogenesis, spectrum, and treatment strategies.
Read ArticleA current review of eosinophilic granulomatosis with polyangiitis (EGPA) provides current recommendations on diagnosis and management.
Read ArticleIn an oral abstract presentation at EULAR 2026, results were shared from a longitudinal observational analysis of the EUSTAR database. The aim was to characterise organ involvement and disease progression – and time to these events – stratified by having a modified disease activity index (
Read ArticleJAMA Network Open has publshed that a simple 2-gene blood test may aid the earlier diagnosis of Kawasaki disease in children with febrile illnesses.
Read ArticleDr. Jack Cush reviews the news, journal reports and best ways to review EULAR 2026.
Read ArticleLate-breaking abstracts presented at the European Alliance of Associations for Rheumatology's (EULAR) annual meeting, held here last week, addressed a wide range of clinical
Read ArticleIt’s time for Rheumatology RoundUp from EULAR 2026 from London, UK. Drs. Artie Kavanaugh and Jack Cush review their choice presentations from the meeting, offering their perspectives on impact and applicability.
Read ArticleMAS, the most severe complication of Still’s disease, is increasingly recognized as a cytokine-driven hyperinflammatory state centered on interferon gamma (IFNγ). Therapeutic advances presented at EULAR 2026 demonstrate both consolidation of established pathways and expansion into novel biologic
Read ArticleThe last day in London was exciting as both the Late-Breaking abstracts and new EULAR guidelines were presented. Guidelines presented addressed several significant unmet need areas including PMR, GCA, Takayasu’s arteritis, Vaccinations in Rheumatic patients, Imaging in spondyloarthritis and
Read Article
Links:
B-cell targeting has moved to the centre of IgG4-related disease treatment, with inebilizumab, a CD19 depleter, as the recent benchmark. At EULAR 2026, INDIGO tested whether the disease can be controlled by switching B cells off rather than depleting them.
Read Article
Links:
Links:
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.